Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

Oscotec, Inc. engages in the development, manufacture and sale of pharmaceutical products. The company operates through the following business divisions: New drug, and Medical materials. Its products include drugs for osteoporosis, arthritis, periodontal disease and cancer, functional food ingredients, dental bone graft materials, dental membrane, and dental supplies. The company was founded on December 8, 1998 and is headquartered in Seongnam-si, South Korea.

Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration

Société des Produits Nestlé SA engages in the manufacture and distribution of food, pharmaceutical, medical, and cosmetic products. The company was founded on December 15, 1936 and is headquartered in Vevey, France.

Caregen Co., Ltd. engages in the development of cosmetic products. Its products include products for professional therapy, home care products, food and beverages, and others. The company was founded on August 23, 2001 and is headquartered in Anyang-si, South Korea.

Cephalon Australia Pty Ltd. developed therapeutic products. The company was founded in 1985 and was headquartered in Macquarie Park, Australia.

Amgen Fremont, Inc., a subsidiary of Amgen, Inc., is a company headquartered in the United States. The firm manufactures monoclonal antibody therapies for anti-cancer medicine.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.

Immunex Corporation develops, manufactures, and markets therapeutic products for the treatment of cancer, infectious diseases, and autoimmune disorders. It offers products, such as Enbrel that is used in the treatment of rheumatoid arthritis; Novantrone, which is used to treat acute nonlymphocytic leukemia and pain associated with prostate cancer; and Leukine for use in bone marrow transplant patients. The company has franchise operations. It has a strategic alliance with American Home Products. The company was founded in 1981 and is based in Seattle, Washington. As of July 15, 2002, Immunex Corporation was acquired by Amgen, Inc.

Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA.

CuraGen Corporation is a biopharmaceutical development company that develops novel therapeutics for the treatment of cancer in the United States and Europe. Its therapeutics is based on novel targets from the human genome that play a role in proven mechanisms underlying disease. The Company's strategy continues to be focused on advancing its pipeline of pipeline of protein, antibody, and small molecule drugs in the areas of oncology, inflammatory diseases, and diabetes, promising therapeutics through clinical and preclinical development. CuraGen Corporation was founded in 1991 and is headquartered in Branford, Connecticut. As of October 1, 2009, CuraGen Corporation operates as a subsidiary of Celldex Therapeutics, Inc.

Beijing Jiquan Biotechnology Co., Ltd., established on 2016-08-09, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Biochemical product technology research and development;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Specialty Chemicals Sales(Free of Hazardous Chemicals);Drug testing equipment sales;Sales of special instruments and meters for agriculture, forestry, animal husbandry and fishery;Cosmetics Wholesale;software development.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Drug Wholesale;Class III medical device business;food sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

PH Therapeutics Ltd. engages in the research and development of biological treatments. It develops novel antibody therapies to treat the orphan disease Pulmonary Arterial Hypertension. The company was founded in 2013 by Allan Lawrie and is headquartered in Leeds, the United Kingdom.

Osteometer Biotech AS is a Danish private company located in Herlev that develops treatments for bone disorders.

The Group's principal activity is developing antibody therapeutic products. It operates in Australia and the United States.

Part of MOH Holdings Pte Ltd., Singapore Health Services Pte Ltd. is a Singaporean company located in Singapore. The firm provides medical services. Ivy Ng is the CEO, in this role since 2012.